(Q37622799)

21 August 2017

1 reference

title

Iron chelation therapy in the management of thalassemia: the Asian perspectives (English)

1 reference

21 August 2017

0 references

1 reference

Vip Viprakasit

1

1 reference

21 August 2017

Chan Lee-Lee

2

1 reference

21 August 2017

Quah Thuan Chong

3

1 reference

21 August 2017

Kai-Hsin Lin

4

1 reference

21 August 2017

Archrob Khuhapinant

5

1 reference

21 August 2017

publication date

29 October 2009

1 reference

International Journal of Hematology

21 August 2017

published in

1 reference

21 August 2017

volume

90

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

435-445

1 reference

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

21 August 2017

cites work

1 reference

12 December 2020

Inherited haemoglobin disorders: an increasing global health problem

1 reference

12 December 2020

1 reference

12 December 2020

Liver iron concentrations and urinary hepcidin in beta-thalassemia

1 reference

12 December 2020

Surviving with thalassemia major: the Italian experience

1 reference

12 December 2020

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

1 reference

12 December 2020

Objectives and mechanism of iron chelation therapy

1 reference

12 December 2020

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

1 reference

12 December 2020

Impact of a national beta-thalassemia carrier screening program on the birth rate of thalassemia major

1 reference

12 December 2020

Oral deferiprone for iron chelation in people with thalassaemia

1 reference

12 December 2020

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

1 reference

12 December 2020

Iron chelation therapy

1 reference

12 December 2020

Prenatal diagnosis and screening of common genetic diseases in Hong Kong.

1 reference

12 December 2020

Clinical and hematologic aspects of hemoglobin E beta-thalassemia

1 reference

12 December 2020

Clinical hemoglobinopathies: iron, lungs and new blood

1 reference

12 December 2020

Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver

1 reference

12 December 2020

Safety of oral iron chelator deferiprone in young thalassaemics

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

12 December 2020

Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study

1 reference

12 December 2020

Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.

1 reference

12 December 2020

Early prenatal diagnosis of beta-thalassaemia in Singapore

1 reference

12 December 2020

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

1 reference

12 December 2020

MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

1 reference

12 December 2020

Beta-thalassemia major in Malaysia, an ongoing public health problem

1 reference

12 December 2020

New advances in iron chelation therapy

1 reference

12 December 2020

Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia

1 reference

12 December 2020

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

1 reference

12 December 2020

Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis

1 reference

12 December 2020

The thalassemias and related disorders.

1 reference

12 December 2020

Prevention of beta-thalassemia major by antenatal screening in Hong Kong

1 reference

12 December 2020

1 reference

12 December 2020

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

1 reference

12 December 2020

Iron-chelating therapy and the treatment of thalassemia.

1 reference

12 December 2020

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

1 reference

12 December 2020

Exjade (ICL 670): A new oral iron chelator

1 reference

12 December 2020

Hemoglobinopathies in Southeast Asia: molecular biology and clinical medicine

1 reference

12 December 2020

Iron deficiency and overload.

1 reference

12 December 2020

Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients

1 reference

12 December 2020

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

1 reference

12 December 2020

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia

1 reference

12 December 2020

Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.

1 reference

12 December 2020

LPI-labile plasma iron in iron overload

1 reference

12 December 2020

Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.

1 reference

12 December 2020

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

De novo deletion within the telomeric region flanking the human alpha globin locus as a cause of alpha thalassaemia

1 reference

12 December 2020

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia

1 reference

12 December 2020

Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients

1 reference

12 December 2020

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

1 reference

12 December 2020

Recent developments in iron chelation therapy

1 reference

12 December 2020

Monitoring and treatment of iron overload: state of the art and new approaches.

1 reference

12 December 2020

10.1007/S12185-009-0432-0

Identifiers

DOI

1 reference

21 August 2017

1 reference